Israeli Researchers Developing PCR Test Gauging which Patients Have Cancer-linked BRCA1/2 Mutations | GenomeWeb

By identifying genes that are differentially expressed in carriers of BRCA1 and BRCA2 mutations, researchers in Israel are working on developing a test that, if validated, might offer a new approach to gauging people's risk of hereditary breast and ovarian cancer.

Furthermore, since this PCR-based test would gauge the expression of genes other than BRCA1 and BRCA2, the researchers, if they are successful, may have found a true workaround to Myriad Genetics' BRCA gene patents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.